Back to search

University of South Florida

Utilizing Systems Level Approaches to Identify Key Mechanisms of Drug Resistance in BRAF Mutated Melanoma

Abstract

dc:description

In the last four years, seven new drugs have been FDA approved for the treatment of late stage melanoma, for the field of melanoma, this marks an incredibly exciting. Three of these new therapies, vemurafenib, dabrafenib and trametinib are small molecule kinase inhibitors that target the MAPK pathway and as such have been approved for the treatment of BRAFV600 mutant melanomas. Yet despite recent advances, mechanisms of intrinsic and acquired BRAF inhibitor resistance continue to undermine uniform and long-lasting therapeutic responses. Several studies have shown that the reactivation of MAPK signaling is a critical event leading to BRAF inhibitor resistance. These studies lead to the evaluation and subsequent FDA approval of frontline BRAF (dabrafenib) plus MEK (trametinib) inhibitors to delay drug resistance. Though this approach has meaningful clinical benefit, there are still a number of patients who do not respond to therapy or who, through unknown mechanisms, succumb to refractory disease. In an effort to identify drivers of MAPK inhibitor resistance, several studies have relied on traditional genomics methods. While gene-based approaches have guided precision medicine, they do not address the dynamics of the global signaling changes that occur following acquired resistance. The dissertation herein will describe our efforts to fill these gaps of knowledge and will expand upon the evolution and development of our understanding of intrinsic and acquired MAPK pathway inhibitor resistance. This work will elaborate on our early understanding of single agent BRAF inhibitor resistance, the use of genomic and proteomic approaches to further elucidate these mechanisms, and evidence based approaches to delay and overcome single agent BRAF inhibitor resistance. This work will describe global phosphoproteomic and bioinformatics methodologies to elucidate the underlying processes of both single (BRAF) and dual agent (BRAF plus MEK) inhibitor resistance as well as strategies to constrain dual agent BRAF plus MEK inhibitor resistance.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (Ph.D.)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Cell Biology, Microbiology, and Molecular Biology
Grantor
University of South Florida
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Paraiso, Kim H.T.
Contributors dc:contributor
  • Keiran Smalley, Ph.D.
  • Geoffrey Gibney, MD.
  • Eric Haura, MD.
  • Conor Lynch, Ph.D.
  • Alvaro Monteiro, Ph.D.

Subjects

dc:subject × 8

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.usf.edu/etd/5552

Chain of custody

source
Harvested from
University of South Florida
Base URL
digitalcommons.usf.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Paraiso, Kim H.T.. Utilizing Systems Level Approaches to Identify Key Mechanisms of Drug Resistance in BRAF Mutated Melanoma. Dissertation thesis, University of South Florida, 2015. https://digitalcommons.usf.edu/etd/5552